3. Insmed Incorporated (NASDAQ:INSM)
Stock Upside: 111.74%
Market Capitalization: $20.44 billion
Number of Hedge Fund Holders: 67
Insmed Incorporated (NASDAQ:INSM) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, Cantor Fitzgerald reaffirmed its Overweight rating on Insmed Incorporated (NASDAQ:INSM) and raised its price target from $230 to $235.
The firm pointed to an upcoming data release for Insmed’s experimental lung drug TPIP as a potential catalyst that investors may be underestimating. TPIP, which stands for Treprostinil Palmitil Inhalation Powder, is an inhaled therapy Insmed is developing for pulmonary arterial hypertension (PAH).
According to Cantor Fitzgerald, it has been roughly a year since Insmed first presented the Phase 2b clinical trial results for TPIP in PAH. The firm sees the next data release as a moment that could meaningfully revive investor interest in the drug. This data is a one-year open label extension update expected in Q3 2026. For context, an open label extension is the phase of a clinical study where all patients are given the actual drug and monitored over a longer period, and the data from this phase typically gives a clearer picture of how durable and safe the treatment is over time.
The firm noted that if the next data release provides robust results, the market may shift focus from Brinsupri, Insmed’s drug for non-cystic fibrosis bronchiectasis. This is because the market is significantly undervaluing TPIP just because Brinsupri posted blowout revenue at the end of Q1 2026.
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company. It focuses on developing and commercializing therapies for serious and rare diseases. One of its lead approved product is ARIKAYCE, an inhaled antibiotic delivered via the Lamira Nebulizer System.
